Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Emopwering people to improve their musculoskeletal health through exercise. TrackActive is a physical health app that assesses a person's conditions, health and habits and delivers a personalised programme consisting of advice and exercises that adapt as the person progresses. The app is developed using rehabilitative exercise data, clinical algorithms and AI. The app can be used by organisations to view anonymised information on the health of their employees or customers and is distributed via public health, corporate and insurance partners.
TrackActive will be monetised via the aforementioned partners, who will pay an ongoing monthly subscription from £25 per month. This figure may increase depending on the health practitioners using the service. TrackActive's content, such as articles, video and images, can also be licensed to partners. Funds will be allocated towards developing the product further, with the inclusion of an Android version, admin dashboards, evidence-based content and regular updates to the app.
days to go:
Expired
investment:
£253,598
Flat Cap Hotels (FCH) own and operate hotels, restaurants, bars and pubs. They specialise in locally sourced British menus and homely accomodation. FCH currently own two establishments; The Vicarage and The Courthouse.
days to go:
Expired
investment:
£170,030
Olberon is a UK based medical device innovations company seeking to raise funds for manufacturing and the sale of Vacuderm which is a device designed to assist with childrens cannulation procedure. Olberon Ltd has already got a strong portfolio of patented medical innovations and two medical devices which are market ready.
days to go:
Expired
investment:
£5,634
Howsy is a property management app that aims to make renting a satisfactory experience for landlords and tenants. The company claims to have created a digital ecosystem that removes traditional agents, bringing down the cost of managing a property by an estimated 75% and delivering satisfactory customer service. Howsy has 7,000 properties on its platform mixed between recurring revenue and one-off customers. It has also acquired two of the largest online agents in the UK, Upad and Happy Tenant Company, in December 2019 and September 2020, respectively. Howsy asserts that it has achieved a 130% year-on-year revenue growth despite the COVID-19 pandemic and has featured in press entities like Forbes, The Guardian, TechCityNews, and Startups.co.uk, amongst others. It will use the investment for working capital allocation across marketing, general/admin, and technology. It will also use the funds to provide a stable runway to its Series A funding round, which it hopes to complete by January 2022.
days to go:
Expired
investment:
£824,280
Howsy is an online marketplace for renting. Howsy does away with traditional over-priced and under-serviced lettings model, bringing down the cost of managing a property by an estimated 75%. Their team of 81, operate across three locations—two in the UK and one in South East Asia. The company has also been featured in publications such as Forbes and The Guardian as well as portals such as TechCityNews and Startups.co.uk. The company will use the investment to build a digital service that makes renting easier, qualify for the 'Future Fund', a government support package for start-ups, and towards building working capital and growth marketing.
days to go:
Expired
investment:
£2,346,770
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.
days to go:
Expired
investment:
£522,689
